2 completed, 1 active not recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
Follow Delfi Diagnostics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer Ability to order FirstLookâ˘, Continuing Medical Education for Lung Cancer - Lung Cancer | Not applicable | Completed | Delfi Diagnostics Inc. | 28 | 2023-10-31 | 2025-11-24 |
| CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung Blood Sample Collection - Lung Cancer | Active not recruiting | Delfi Diagnostics Inc. | 11935 | 2022-04-07 | 2026-03-19 | |
| DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) Blood Sample Collection - Lung Cancer, Head and Neck Cancer | Completed | Delfi Diagnostics Inc. | 2992 | 2021-03-22 | 2025-08-08 |
Lung Neoplasms (3) · Adenocarcinoma (1) · Colorectal Neoplasms (1) · Disease (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Kidney Neoplasms (1) · Liver Neoplasms (1) · Lung Diseases (1) · Pancreatic Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Skin Neoplasms (1) · Stomach Neoplasms (1) · Thoracic Neoplasms (1)
United States (3) · Puerto Rico (2)
Luke RG Pike, MD, DPhil (1) · Peter Bach, MD (1) · Peter Mazzone, MD, MPH (1)